Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pentostatin in Prolymphocytic Leukemia: Phase II Trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group

Published:1993-04-21 Issue:8 Volume:85 Page:658-662
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

Dohner H.,Ho A. D.,Thaler J.,Stryckmans P.,Sonneveld P.,Witte T. d.,Lechner K.,Lauria F.,Bodewadt-Radzun S.,Suciu S.,Solbu G.,Witt B.,Hunstein W.,Zittoun R.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/85/8/658/7807622/85-8-658.pdf

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B-Cell Prolymphocytic Leukemia: Clinical Profile and Treatment Outcomes at a Tertiary Cancer Center in South India;Oncology Journal of India;2023

2. Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia;European Journal of Haematology;2022-08-05

3. Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors;Molecular Therapy;2021-09

4. Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax;Leukemia Research Reports;2021

5. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene;Biomedicine & Pharmacotherapy;2020-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP